Table of Contents

Quantitative minimal residual disease assessments predict progression-free survival in CLL patients treated with FC with or without rituximab: a prospective analysis in 471 patients from the CLL-8 trial

NE Oncology Issue - February 2009 Boettcher S, et al. ASH 2008: Abstract 326 Background Data correlating clinical outcome with achievement of minimal residual disease (MRD) are of interest as increased complete response (CR) rates are achieved with advances in...

Download Journal

oncol_issue

50th Anniversary Tribute to ASH

dr-Connors
Joseph M. Connors, MD
Dr. Joseph M. Connors is Clinical Professor at the University of British Columbia; and Clinical Director of the Centre for Lymphoid Cancer, Chair of the Lymphoma Tumour Group, and Chair of the Research Ethics Board at the BC Cancer Agency. He is best known for his clinical investigations into the treatment of Hodgkin’s lymphoma, nonHodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. He has served as the chairman of the Hematology Site Committee for the National Cancer Institute of Canada Clinical Trials Group, as a liaison member between the American Society of Clinical Oncology and the American College of Radiology, and as a vicechairman of the ASH Educational Committee. Dr. Connors is a founding member and coordinator of the Scientific Advisory Board for the Lymphoma Foundation Canada.

Investigator Commentaries

dr-Hallek
Michael Hallek, MD
Dr. Michael Hallek is Professor of Medicine, and Director and Chair of the Department of Internal Medicine I at the University of Cologne in Cologne, Germany, where he oversees internal medicine, hematology, hemostaseology, oncology, intensive care, infectious diseases, and immunology. From 1994–2005, Dr. Hallek was head of the Gene Therapy Program at the Gene Center of the University of Munich and of the Clinical Cooperation Group for Gene Therapy at the National Centre for Research on Environment and Health (GSF) in Munich. In 2007, Dr. Hallek was appointed Director of the Center of Integrated Oncology (CIO), the joint comprehensive cancer centre of the Universities of Cologne and Bonn. Since 1994, he has been Chair of the German CLL Study Group. Dr. Hallek is the principal investigator for the CLL-8 clinical trial.

dr-Robak
Tadeusz Robak, MD, PhD
Dr. Tadeusz Robak is Professor of Hematology at the Medical University of Lodz and Chief of the Department of Hematology at the Copernicus Memorial Hospital in Lodz, Poland. In 1996–2002, Professor Robak was Vice-rector and Rector of the Medical University of Lodz. Professor Robak is also editor-in-chief of Acta Haematologica Polonica and vice-president of the Polish Leukemia Study Group (PALG). His particular research emphasis has been on the application of purine analogs and monoclonal antibodies in the treatment of leukemia and lymphoma. Professor Robak has published more than 500 journal articles, 350 abstracts, and 15 books or chapters. He is the principal investigator for the REACH clinical trial.

Canadian Perspectives

dr-FRCP
Chaim Shustik, MD, FRCP(C)
Dr. Chaim Shustik is a McGill Professor of Medicine and a staff physician in the Division of Hematology at the Royal Victoria Hospital in Montreal. His primary area of interest is in the treatment of hematologic malignancies. Dr. Shustik holds the Louis Lowenstein Chair in Hematology and Oncology. He is a member of the Scientific Advisory Board of the International Myeloma Foundation.

dr-Sehn
Laurie H. Sehn, MD, MPH
Dr. Laurie H. Sehn is Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia in Vancouver. She has been a medical oncologist and clinical investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of the Lymphoma Foundation Canada (LFC) since 2002 and is now Director of Research Fellowships for the LFC. Her research interests include the lymphoid cancers with particular focus on the biology and treatment of large-cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.

dr-Sehn
John Kuruvilla, MD
Dr. John Kuruvilla is Assistant Professor of Medicine at the University of Toronto and a clinical investigator in the Department of Medical Oncology at Princess Margaret Hospital in Toronto. He is a hematologist and member of the Lymphoma Program and the Autologous and Allogeneic Stem Cell Programs. His research interests include novel drug development in lymphoid malignancies and the study of stem cell transplant strategies, and clinical trials in these disorders.